173422-30-5

Usage

Uses

Used in Pharmaceutical Industry:
(1S,2S,3R,4S,5R,7S,8R,10R,13S)-4-acetoxy-2-benzoyloxy-5,20-epoxy-9-oxo-1,10,13-trihydroxytax-11-ene is used as a potential chemotherapeutic agent for the treatment of cancer. Its taxane backbone and functional groups contribute to its medicinal properties, making it a candidate for further research and development in oncology. Taxanes are known for their ability to stabilize microtubules, disrupt cell division, and induce apoptosis in cancer cells, which is why (1S,2S,3R,4S,5R,7S,8R,10R,13S)-4-acetoxy-2-benzoyloxy-5,20-epoxy-9-oxo-1,10,13-trihydroxytax-11-ene holds promise in the development of new cancer therapies.

Upstream product

• 150930-83-9 7-deshydroxy baccatine III 
• 184586-80-9 C₃₀H₃₆O₁₀ 
• 170575-25-4 7-OTf-10DAB 
• 184586-79-6 C₃₄H₃₈N₂O₁₁S 
• 478161-64-7 (1S,2S,3R,4S,5R,7S,8S,10R,13S)-4-acetoxy-2-benzoyloxy-5,20-epoxy-10-formyloxy-1,13-dihydroxy-9-oxo-7-trifluoromethanesulfonyloxytax-11-ene 
• 184586-78-5 (1S,2S,3R,4S,5R,7S,8S,10R,13S)-4-acetoxy-2-benzoyloxy-5,20-epoxy-10-formyloxy-9-oxo-1,7,13-trihydroxytax-11-ene 
• 32981-86-5 10-deacetylbaccatin III 
• 272129-02-9 (1S,2S,3R,4S,5R,7S,8R,10R,13S)-4-acetoxy-2-benzoyloxy-5,20-epoxy-9-oxo-1,10,13-trihydroxytax-6,11-diene 

Downstream Products

• 173422-31-6 C₃₁H₃₈O₉S₂ 
• 333754-43-1 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-acetoxy-2-benzoyloxy-9,10-[(1S)-2-(dimethylamino)ethylidenedioxy]-5,20-epoxy-1-hydroxytax-11-en-13-yl (2R,3S)-3-(tert-butoxycarbonylamino)-3-(3-fluoro-2-pyridyl)-2-triisopropylsilyloxypropionate 
• 1353548-60-3 C₃₃H₄₅NO₉ 
• 184586-82-1 C₃₂H₄₀O₉ 
• 333327-25-6 C₃₂H₄₀O₈ 
• 184586-13-8 C₃₂H₄₂O₉ 
• 184586-81-0 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-(acetoxy)-2-(benzoyloxy)-5,20-epoxy-1,9,10,13-tetrahydroxytax-11-ene 

Relevant academic research and scientific papers

Taxane Compounds, Compositions And Methods

The present invention provides a method for the preparation of orally available pentacyclic taxane compounds, as well as intermediates useful in their preparation.

New highly active taxoids from 9β-dihydrobaccatin-9,10-acetals. Part 2

To investigate structure-activity relationships of the 9,10-acetal-9β-dihydro taxoids, we modified the 7-hydroxyl groups of the 9,10-acetonide-3′-(4-pyridyl) analogue to deoxy, methoxy, α-F, and 7β,8β-methano group. As a result of this study, we found that the 7-deoxy analogue was the strongest among these analogues. In addition, we found that the 7-deoxy-3′-(4-pyridyl) and 7-deoxy-3′-(2-pyridyl) analogues showed stronger activity against cell lines expressing P-glycoprotein than the corresponding 3′-phenyl analogue.

A new method for synthesis of 7-deoxytaxane analogues by hydrogenation of Δ6,7-taxane derivatives

A new method for the synthesis of 7-deoxytaxane analogues has been established through hydrogenation of Δ6,7-taxane derivatives. Among several catalysts examined, Pd-C was found to be a most effective catalyst for the preparation of target compound.

Orally active docetaxel analogue: Synthesis of 10-deoxy-10-C-morpholinoethyl docetaxel analogues

To improve cytotoxicity of 10-deoxy-10-C-morpholinoethyl docetaxel analogues against various tumor cell lines including resistant cells expressing P-glycoprotein (P-gp), we modified the 7-hydroxyl group to hydrophobic groups (methoxy, deoxy, 6,7-olefin, α-F, 7-β-8-β-methano, fluoromethoxy). Among these analogues, the 7-methoxy analogue showed the strongest cytotoxicity. This analogue showed potent activity against B16 melanoma BL6 in vivo by oral administration.